Title: Lansoprazole
CAS Registry Number: 103577-45-3
CAS Name: 2-[[[3-Methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
Additional Names: 2-(2-benzimidazolylsulfinylmethyl)-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine
Manufacturers' Codes: A-65006; AG-1749
Trademarks: Agopton (Takeda); Lansox (Takeda); Lanzor (Aventis); Limpidex (Sigma-Tau); Ogast (Takeda); Prevacid (TAP); Takepron (Takeda); Zoton (Wyeth)
Molecular Formula: C16H14F3N3O2S
Molecular Weight: 369.36
Percent Composition: C 52.03%, H 3.82%, F 15.43%, N 11.38%, O 8.66%, S 8.68%
Literature References: Gastric proton-pump inhibitor. Prepn: A. Nohara, Y. Maki, EP 174726; eidem, US 4628098 (both 1986 to Takeda). HPLC determn in plasma: T. Uno et al., J. Chromatogr. B 816, 309 (2005). Pharmacology: H. Satoh et al., J. Pharmacol. Exp. Ther. 248, 806 (1989). Mechanism of action study: H. Nagaya et al., ibid. 252, 1289 (1990). Clinical pharmacology and effect on human gastric acid secretion: P. Müller et al., Aliment. Pharmacol. Ther. 3, 193 (1989). Review of pharmacology and clinical experience: H. D. Langtry, M. I. Wilde, Drugs 54, 473-500 (1997). Comparative clinical trial with esomeprazole in erosive esophagitis: C. W. Howden et al., Clin. Drug Invest. 22, 99 (2002).
Properties: mp 178-182° (dec).
Melting point: mp 178-182° (dec)
Therap-Cat: Antiulcerative.
Keywords: Antiulcerative; Gastric Proton Pump Inhibitor. |